Literature DB >> 15292775

Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults II: cost-effectiveness analysis.

.   

Abstract

OBJECTIVES: The objectives of this study were to estimate the cost-effectiveness of unilateral cochlear implantation for postlingually deafened adults; to study the impact on cost-effectiveness of relaxing criteria of candidacy to include patients who benefit from acoustic hearing aids; and to study the further impact of age at implantation and duration of profound deafness before implantation.
DESIGN: This prospective cohort study was carried out in 13 hospitals with four groups of severely to profoundly hearing-impaired subjects distinguished by their preoperative ability to identify words in prerecorded sentences when aided acoustically. The groups represent a progressive relaxation of criteria of candidacy: Group I (N=134) scored 0% correct without lipreading and did not improve their lipreading score significantly when aided; group II (N=93) scored 0% without lipreading but did improve their lipreading score significantly when aided; group III (N=53) scored 0% without lipreading when the ear to be given an implant was aided but between 1% and approximately 50% when the other ear was aided; and group IV (N=31) scored between 1% and approximately 50% without lipreading when the ear to be given an implant was aided. Lifetime costs to the UK National Health Service of providing and maintaining a cochlear implant were estimated for each subject. The gain in health utility from cochlear implantation was estimated with the Mark III Health Utilities Index and was combined with life expectancy to estimate the number of quality-adjusted life-years (QALYs) that would be gained from cochlear implantation. Cost/QALY ratios were calculated by means of the Net Benefit technique and were compared with an upper limit of acceptability of 50,000 euros/QALY.
RESULTS: Averaged over the whole cohort, the cost of gaining a QALY was 27,142 euros (95% confidence interval, 24,532 euros to 30,323 euros); 203 of 311 (67%) of the cohort displayed cost/QALY ratios more favorable than 50,000 euros/QALY. The average cost of gaining a QALY increased from group I (24,032 euros) to groups II (27,062 euros) and IV (27,092 euros) to group III (39,009 euros). Cost/QALY varied with age at implantation from 19,223 euros for subjects who were younger than 30 yr of age to 45,411 euros for subjects who were older than 70 yr of age. Cost/QALY was unacceptable because of minimal gain in health utility for the subset of groups I and II, who were given implants in ears that had been profoundly deaf for more then 40 yr and for the subset of groups III and IV, who were given implants in ears that had been profoundly deaf for more than 30 yr.
CONCLUSIONS: Cochlear implantation was a cost-effective intervention for the majority of subjects, including the group given implants when older than 70 yr of age. Relaxation of criteria of candidacy for cochlear implantation reduces cost-effectiveness. Prioritization of the provision of cochlear implantation should take duration of profound deafness in the ear to be given an implant into account, as well as preoperative word recognition performance.

Entities:  

Mesh:

Year:  2004        PMID: 15292775     DOI: 10.1097/01.aud.0000134550.80305.04

Source DB:  PubMed          Journal:  Ear Hear        ISSN: 0196-0202            Impact factor:   3.570


  22 in total

Review 1.  The multiple-channel cochlear implant: the interface between sound and the central nervous system for hearing, speech, and language in deaf people-a personal perspective.

Authors:  Graeme M Clark
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-05-29       Impact factor: 6.237

2.  Inferior frontal gyrus activation predicts individual differences in perceptual learning of cochlear-implant simulations.

Authors:  Frank Eisner; Carolyn McGettigan; Andrew Faulkner; Stuart Rosen; Sophie K Scott
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 3.  Recent advances in hearing restoration.

Authors:  Kunal Kulkarni; Douglas Eh Hartley
Journal:  J R Soc Med       Date:  2008-03       Impact factor: 5.344

4.  Pitch Matching between Electrical Stimulation of a Cochlear Implant and Acoustic Stimuli Presented to a Contralateral Ear with Residual Hearing.

Authors:  Chin-Tuan Tan; Brett Martin; Mario A Svirsky
Journal:  J Am Acad Audiol       Date:  2017-03       Impact factor: 1.664

5.  Further Evidence of the Relationship Between Cochlear Implant Electrode Positioning and Hearing Outcomes.

Authors:  Srijata Chakravorti; Jack H Noble; René H Gifford; Benoit M Dawant; Brendan P O'Connell; Jianing Wang; Robert F Labadie
Journal:  Otol Neurotol       Date:  2019-06       Impact factor: 2.311

Review 6.  [Cochlear implant treatment in Germany].

Authors:  R Jacob; Y Stelzig
Journal:  HNO       Date:  2013-01       Impact factor: 1.284

7.  Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique.

Authors:  Rajan Sharma; Yuanyuan Gu; Teresa Y C Ching; Vivienne Marnane; Bonny Parkinson
Journal:  Appl Health Econ Health Policy       Date:  2019-06       Impact factor: 2.561

8.  Evidence gaps in economic analyses of hearing healthcare: A systematic review.

Authors:  Ethan D Borre; Mohamed M Diab; Austin Ayer; Gloria Zhang; Susan D Emmett; Debara L Tucci; Blake S Wilson; Kamaria Kaalund; Osondu Ogbuoji; Gillian D Sanders
Journal:  EClinicalMedicine       Date:  2021-05-08

9.  The cost of cochlear implantation: a review of methodological considerations.

Authors:  Costa Nadège; Garnault Valérie; Ferlicoq Laura; Derumeaux-Burel Hélène; Bongard Vanina; Deguine Olivier; Fraysse Bernard; Molinier Laurent
Journal:  Int J Otolaryngol       Date:  2011-10-17

Review 10.  Systematic review of the scientific literature on the economic evaluation of cochlear implants in adult patients.

Authors:  G Turchetti; S Bellelli; I Palla; S Berrettini
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-10       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.